ACST - Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024 | Benzinga
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024.
7th Annual Sachs Neuroscience Innovation Forum – (January 7)
Bio One-On-One Partnering – (January 8-9)
13th Annual LifeSci Partners Corporate Access Event – (January 10)
Mr. Kohli will be presenting and available to meet with investors and potential strategic partners on the dates indicated during the three events. His presentation at the Sachs Innovation Forum will be recorded, and will be available on-demand from the Sachs conference website during a virtual session January 16-18, 2024.
To schedule a meeting, contact Mike Moyer at mmoyer@lifesciadvisors.com.
About aneurysmal Subarachnoid Hemorrhage (aSAH)
aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm. Approximately 70% of aSAH patients experience death or dependence, and more than 30% die within one month of hemorrhage. Approximately 50,000 patients in the United States are affected by aSAH per year, based on market research.
About GTX-104
GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous infusion (IV) in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTX-104 facilitates aqueous formulation of ...